Efficacy of NovoSeven® in Bleeding Prophylaxis in Hemophilia

• Status: Completed
• Trial end date: 2005-11-01
• Target enrollment: 0
• Participant gender: Male

Summary

This trial is conducted in Africa, Asia, Europe, South America, and the United States of America (USA).

The purpose of this study is to evaluate the effectiveness of secondary prophylactic treatment with NovoSeven® in haemophilia A and B patients with inhibitors.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novo Nordisk A/S

Criteria

Inclusion Criteria:

• Diagnosis of congenital haemophilia A or B with inhibitors development against FVIII or FIX, respectively

Exclusion Criteria:

• Prophylactic administration of any haemostatic drug within 3 last months prior to entering the trial.